B. Braun and Health-Robotics Announced an Agreement for CytoCare™

B. BraunB. Braun and Health-Robotics announced a long-term and exclusive strategic agreement for B. Braun to exclusively utilize Health-Robotics' IV Admixture Automation Solutions worldwide within the Oncology, Pain Management, Antibiotics, Radio Pharmaca, and all other IV Therapy and Clinical Nutrition. In addition, B. Braun has immediately acquired from Health-Robotics the long-term, exclusive rights to manufacture, assemble, market, license, provide installation and integration services and support for the CytoCare™ Robot in Europe, Latin America, Africa, Oceania, and most of Asia.

With its CytoCare™ Robot, Health-Robotics has developed the first totally automated system for safe preparation of patient-specific hazardous IV doses. "CytoCare™ constitutes a breakthrough advance for patient and clinician's safety," says Werner Rainer, General Manager, Health-Robotics. "This strategic agreement with B. Braun combines state-of-the-art technologies to achieve the accuracy and sterility that providers require for automating patient-specific IV admixture preparations with B. Braun’s world-class organization. The resulting technology is the only totally automated system for handling hazardous IV admixtures available in the market. In addition, CytoCare™ is the only IV Admixtures Preparation Automated solution that enables global health care providers with flexibility to utilize a wide range of final IV containers", he adds. "Everyone within our company and customer base is extremely proud of being selected by an organization of the caliber and outstanding reputation of B. Braun."

This agreement tightly fits with B. Braun's mission of becoming customer's first choice for infusion therapy and providing world-class technology for IV pharmacy operations. Markus Strotmann, Senior Vice President of Strategic Marketing for B. Braun Melsungen AG notes, "B. Braun is very pleased to reach a long-term strategic agreement with Health-Robotics. We have closely worked with Health-Robotics for approximately one year market-testing the concept of CytoCare™ and conducting technical due diligence. We hope that this strategic collaboration with Health-Robotics grows over time in delivering improved patient safety solutions to B. Braun's customers in areas beyond Oncology and to continue the integration work we initiated last year with our industry-leading Ecoflac and EasyPump solutions. Such an end-to-end solution for IV Therapy will also help drive down the complexity, medication errors, initial cost and daily operating expenses - which are key issues for healthcare organizations."

About B. Braun Melsungen AG
B. Braun supplies the global healthcare market with products for anesthesia, intensive medicine, cardiology, extra corporeal blood treatment and surgery, as well as services for hospitals, general practitioners and the homecare sector. Through dialogue with those who are using B. Braun's products on a daily basis, the company is continually gaining new knowledge, which it incorporates into product development. In this way, the company contributes with innovative products and services towards optimizing working procedures in hospitals and medical practices all over the world and improving safety – for patients, doctors and nursing staff. For more information, please visit http://www.bbraun.com.

About Health Robotics GmbH
Health Robotics is the leading global supplier in the automation of life-critical intravenous patient-specific medication preparation, especially chemotherapy. Its mission is to provide healthcare facilities with automated solutions that ease pharmacies’ growing pressures by improving patient safety, reducing life-threatening medication errors and contamination risks, working more efficiently, increasing throughput, and containing spiraling chemotherapy expenses. For more information, please visit http://www.health-robotics.com.

Most Popular Now

AI Distinguishes Glioblastoma from Look-…

A Harvard Medical School–led research team has developed an AI tool that can reliably tell apart two look-alike cancers found in the brain but with different origins, behaviors, and treatments. The...

Overcoming the AI Applicability Crisis a…

Opinion Article by Harry Lykostratis, Chief Executive, Open Medical. The government’s 10 Year Health Plan makes a lot of the potential of AI-software to support clinical decision making, improve productivity, and...

Smart Device Uses AI and Bioelectronics …

As a wound heals, it goes through several stages: clotting to stop bleeding, immune system response, scabbing, and scarring. A wearable device called "a-Heal," designed by engineers at the University...

Dartford and Gravesham Implements Clinis…

Dartford and Gravesham NHS Trust has taken a significant step towards a more digital future by rolling out electronic test ordering using Clinisys ICE. The trust deployed the order communications...

AI Body Composition Measurements can Pre…

Adiposity - or the accumulation of excess fat in the body - is a known driver of cardiometabolic diseases such as heart disease, stroke, type 2 diabetes, and kidney disease...